Skip to content

Study · Animal study (in vivo) · 2022

4 results

A Water-Soluble Quercetin Conjugate with Triple Targeting Exerts Neuron-Protective Effect on Cerebral Ischemia by Mitophagy Activation.

Cen J, Zhang R, Zhao T, Zhang X, Zhang C, Cui J, Zhao K, Duan S, Guo Y

Advanced healthcare materials13 Sept 2022Cited by 24 (Europe PMC)

PMID36071574 (opens in a new tab)DOI10.1002/adhm.202200817 (opens in a new tab)PepBankPUB-36071574
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In vitro and in vivo, SS31 attached to the HA-QT conjugate increased drug penetration into the blood-brain barrier four-fold.

    In plain wordsIn lab and animal tests, adding SS31 to the quercetin conjugate raised its passage across the blood-brain barrier four-fold.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseDrug penetration into the blood-brain barrier
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro and in vivo results shows that SS31 can four-fold increase the drug penetration into BBB without any toxicity.
    1 context sentence
    Summary · context
    Next, a novel delivery system SS31-HA-QT is prepared by further modification with SS31, a polypeptide capable of penetrating the blood-brain barrier (BBB) and indiscriminately targeting mitochondria.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In vitro and in vivo, SS31 increased blood-brain barrier penetration without any toxicity.

    In plain wordsIn lab and animal tests, adding SS31 raised brain penetration and no toxicity was seen.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeToxicity of SS31 in the conjugate
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro and in vivo results shows that SS31 can four-fold increase the drug penetration into BBB without any toxicity.
    1 context sentence
    Summary · context
    Next, a novel delivery system SS31-HA-QT is prepared by further modification with SS31, a polypeptide capable of penetrating the blood-brain barrier (BBB) and indiscriminately targeting mitochondria.

Studies that did not test the peptide alone2

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism

    The conjugate SS31-HA-QT achieved mitochondrial targeting of damaged neurons through its SS31 part.

    In plain wordsIn lab and animal tests, the SS31-quercetin conjugate reached the mitochondria of damaged nerve cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableMitochondrial targeting of damaged neurons by SS31-HA-QT
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Importantly, the mitochondrial targeting of damaged neurons is also achieved by SS31.
    1 context sentence
    Summary · context
    Next, a novel delivery system SS31-HA-QT is prepared by further modification with SS31, a polypeptide capable of penetrating the blood-brain barrier (BBB) and indiscriminately targeting mitochondria.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism

    The conjugate SS31-HA-QT protected neurons by activating mitophagy, with Akt/mTOR related TFEB and HIF-1α activation.

    In plain wordsIn lab and animal tests, the SS31-quercetin conjugate protected nerve cells by switching on removal of damaged mitochondria.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseNeuron protection by mitophagy activation
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Further studies confirmed that SS31-HA-QT exerted neuron-protection by activating mitophagy, and its mechanism involved Akt/mTOR related TFEB and HIF-1α activation.
    1 context sentence
    Summary · context
    Next, a novel delivery system SS31-HA-QT is prepared by further modification with SS31, a polypeptide capable of penetrating the blood-brain barrier (BBB) and indiscriminately targeting mitochondria.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.